A long-lasting insecticidal net (LLIN) treated with chlorfenapyr generated a 44% reduction in malaria incidence in children ages 6 months to 10 years and provided “significantly better protection” compared to a standard pyrethroid-only LLIN, according to 24-month data from a Tanzania-based trial published last week in The Lancet.
The study underscored the value of BASF’s dual-ingredient Interceptor G2, according to a press release from IVCC, a Unitaid-backed product development…
The state of the fight:
Moderna shared new Phase 2/3 data supporting the use of Spikevax in children under age 6.
Moderna claimed clinical trial success for its vaccine in children ages 6 months to under 6 years. An interim analysis of Phase 2/3 results showed a “…
The state of the fight:
Medicines Patent Pool sublicensed Pfizer’s Paxlovid to 35 generics manufacturers.
Medigen’s protein subunit vaccine (MVC-COV1901) offered similar safety and immunogenicity for adolescents as it did for adults, the Taipei-based…
The state of the fight:
Moderna pledged permanently to forgo enforcement of its Covid-19 vaccine patents for shots made “in or for” 92 LMICs.
A WHO technical advisory group now “strongly supports urgent and broad access” to Covid-19 booster doses…
Moderna on Monday unveiled a sweeping global health strategy that includes an mRNA manufacturing facility in Kenya, an expanded pledge not to enforce patents on its Covid-19 shot in certain countries, and a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases. But the company also made clear it would pursue these objectives on its own terms, brushing aside activist demands that it share intellectual property with the WHO-led mRNA technology transfer hub in…
The state of the fight:
Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
Pfizer/BioNTech’s Comirnaty is far less protective against infection in children ages…
The state of the fight:
Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…
WHO reportedly added two vaccines to its prequalification list in recent weeks.
Sanofi’s meningococcal ACYW tetanus toxoid-based conjugate vaccine, MenQuadfi, notched PQ status last month, according to WHO records.
Meanwhile, a CNBG announcement last week on Chinese social media stated that its Sabin-based inactivated polio vaccine (sIPV) had won the designation. With this approval, CNBG’s shot beats out Sinovac’s product to become the second prequalified sIPV after LG Chem’s…
WHO has established a “global biomanufacturing training hub” in South Korea that will serve LMICs aspiring to manufacture their own vaccines and therapies, according to a joint announcement Wednesday from the U.N. health agency, the South Korean government and the WHO Academy.
The selected facility outside Seoul has already been training domestic biomanufacturing companies, and will now work with the WHO Academy to expand its curriculum and accommodate researchers from around the…
The state of the fight:
Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
Medigen’s protein subunit…